Role of LMP1 in immune control of EBV infection

Seminars in Cancer Biology

Volumn 11, Issue 6, 2001, Pages 455-460

  Pai, Saparna ^a   Khanna, Rajiv ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antigen processing; Cytotoxic T cells; Epitope; HLA class I; Malignancy; Nuclear antigens; Transformation

Indexed keywords

B LYMPHOCYTE ANTIGEN; CELL ADHESION MOLECULE; CELL NUCLEUS ANTIGEN; CELL PROTEIN; EPITOPE; HLA ANTIGEN CLASS 1; LATENT MEMBRANE PROTEIN 1;

ANTIGEN PRESENTATION; B LYMPHOCYTE; CELL TRANSFORMATION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PERSISTENT INFECTION; PROTEIN EXPRESSION; REVIEW; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS PATHOGENESIS;

EID: 0035204540     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0412     Document Type: Article

References (32)

1. Epstein-Barr virus
2. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases
3. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
4. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design
5. An immunological basis for inhibition of transformation of human lymphocytes by EB virus
6. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: Implications for vaccine development
7. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
8. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
9. Immune regulation in Epstein-Barr virus-associated diseases
10. Tumour surveillance: Missing peptides and MHC molecules
11. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier
12. A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues
13. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T-cell surveillance
14. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses
15. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
16. Upregulation of B7 molecules by the Epstein-Barr virus enhances susceptibility to lysis by a human NK-like cell line
17. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line
18. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA class-I antigen expression
19. Cell biology of antigen presentation
20. LMP1 structure and signal transduction
21. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1
22. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B
23. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo
24. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition
25. Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5′-flanking region
26. Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma
27. Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants
28. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2
29. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease
30. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design
31. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination
32. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: A novel approach to vaccine design